Cardiovascular Drugs Practice Questions

Q: Which beta-blocker possesses antioxidant properties?

Carvedilol. **Explanation:** **Carvedilol** is a unique, third-generation non-selective beta-blocker that also possesses alpha-1 ($\alpha_1$) blocking activity. Its **antioxidant properties** stem from its ability to scavenge free radicals and inhibit lipid peroxidation. This effect is attributed to its carbazole ring structure. By reducing oxidative stress and inhibiting the expression of adhesion molecules, carvedilol provides a "vasoprotective" effect, making it a cornerstone in the management of chronic heart failure (CHF) as it prevents remodeling. **Analysis of Incorrect Options:** * **A. Celiprolol:** A third-generation $\beta_1$-selective blocker with $\beta_2$-agonist and weak $\alpha_2$-blocking activity. It is known for its vasodilatory properties but lacks significant antioxidant effects. * **C. Betaxolol:** A cardioselective ($\beta_1$) blocker primarily used in glaucoma (topical) and hypertension. It does not possess antioxidant or vasodilatory properties. * **D. Propranolol:** A first-generation, non-selective beta-blocker. While it is highly lipid-soluble and has membrane-stabilizing activity, it does not have antioxidant capabilities. **High-Yield Clinical Pearls for NEET-PG:** * **Third-Generation Beta-Blockers:** Divided into Non-selective (Carvedilol, Labetalol) and $\beta_1$-selective (Nebivolol, Betaxolol, Celiprolol). * **Nebivolol:** Another third-generation blocker that causes vasodilation specifically via **Nitric Oxide (NO) release**. * **Heart Failure Trio:** The three beta-blockers proven to reduce mortality in CHF are **Carvedilol, Metoprolol succinate, and Bisoprolol.** * **Metabolic Profile:** Carvedilol is "metabolically neutral" or may improve insulin sensitivity, unlike older beta-blockers which can worsen glycemic control.

Q: Levosimendan is approved in which of the following conditions?

Heart failure. **Explanation:** **Levosimendan** is a novel cardiovascular drug classified as a **Calcium Sensitizer**. It is primarily used in the management of **acutely decompensated heart failure (ADHF)** where conventional therapies are insufficient. **Why Option A is Correct:** Levosimendan exerts its effect through a dual mechanism of action: 1. **Inotropic Effect:** It binds to cardiac **Troponin C** in a calcium-dependent manner. This increases the sensitivity of myofilaments to existing calcium, enhancing myocardial contractility without increasing intracellular calcium levels. Crucially, this improves stroke volume without significantly increasing myocardial oxygen demand or causing arrhythmias. 2. **Vasodilation:** It opens **ATP-sensitive potassium (K+ATP) channels** in vascular smooth muscle, leading to peripheral and coronary vasodilation (Inodilator). This reduces both preload and afterload. **Why Other Options are Incorrect:** * **B & C (Kidney/Liver Failure):** Levosimendan is not a treatment for organ failure in these systems. In fact, its active metabolite (OR-1896) is excreted renally, requiring cautious use or dose adjustment in severe renal impairment. * **D (Endocrine Crisis):** Conditions like thyroid storm or Addisonian crisis require specific hormonal stabilization (e.g., beta-blockers, steroids), not calcium sensitizers. **High-Yield Clinical Pearls for NEET-PG:** * **Unique Feature:** Unlike Dobutamine or Milrinone, Levosimendan does not increase intracellular calcium, making it less likely to cause calcium-overload-induced arrhythmias. * **Inodilator:** It belongs to the "Inodilator" class (Inotrope + Vasodilator). * **Indication:** Short-term treatment of severe ADHF when standard inotropes are inadequate. * **Side Effects:** Hypotension (due to vasodilation) and headache are the most common adverse effects.

Q: Which of the following is used to treat severe pulmonary hypertension?

Bosentan. **Explanation:** **Bosentan** is the correct answer because it is a **non-selective endothelin receptor antagonist (ERA)**. It blocks both $ET_A$ and $ET_B$ receptors, which are responsible for the potent vasoconstrictive and proliferative effects of Endothelin-1. By inhibiting these receptors, Bosentan reduces pulmonary vascular resistance, making it a first-line oral therapy for **WHO Group 1 Pulmonary Arterial Hypertension (PAH)**. **Analysis of Incorrect Options:** * **Angiotensin I (A):** This is a precursor to Angiotensin II. It has no direct therapeutic role in pulmonary hypertension; in fact, its conversion to Angiotensin II would lead to systemic vasoconstriction. * **Omapatrilat (B):** This is a **Vasopeptidase inhibitor** that inhibits both Neprilysin and ACE. While it was studied for systemic hypertension and heart failure, it is not used for pulmonary hypertension and was never FDA-approved due to a high risk of angioedema. * **Endothelin (D):** This is a potent endogenous **vasoconstrictor**. Administering endothelin would severely worsen pulmonary hypertension by causing further narrowing of the pulmonary arteries. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Bosentan is a competitive antagonist at $ET_A$ and $ET_B$ receptors. * **Side Effects:** The most significant side effect is **Hepatotoxicity** (requires monthly LFT monitoring). It is also highly **Teratogenic** (Category X), necessitating a negative pregnancy test before starting therapy. * **Other ERAs:** **Ambrisentan** (selective $ET_A$ blocker) and **Macitentan** (tissue-selective non-selective blocker). * **Other PAH Treatments:** Sildenafil (PDE-5 inhibitor), Epoprostenol (Prostacyclin analogue), and Riociguat (Guanylate cyclase stimulator).

Q: A hypertensive patient on beta-blocker medication develops severe bradycardia. Which of the following is least likely to be the responsible agent?

Pindolol. **Explanation:** The core concept in this question is **Intrinsic Sympathomimetic Activity (ISA)**, also known as partial agonist activity. **Why Pindolol is the correct answer:** Pindolol is a non-selective beta-blocker that possesses significant **Intrinsic Sympathomimetic Activity (ISA)**. Unlike pure beta-blockers, pindolol partially stimulates beta-receptors while simultaneously blocking them from stronger catecholamine stimulation. Because it provides a low level of "background" stimulation, it causes significantly less bradycardia at rest compared to other beta-blockers. In some cases, it may even slightly increase the resting heart rate, making it the least likely agent among the choices to cause severe bradycardia. **Why the other options are incorrect:** * **Metoprolol (A) and Atenolol (D):** These are cardioselective ($\beta_1$) blockers. They lack ISA and are well-known for causing a dose-dependent decrease in heart rate (bradycardia) by blocking $\beta_1$ receptors in the SA and AV nodes. * **Nadolol (B):** This is a long-acting, non-selective beta-blocker without ISA. It is highly potent and frequently associated with significant bradycardia. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-blockers with ISA:** Pindolol, Acebutolol, Alprenolol, and Oxprenolol. (Mnemonic: **P**a**A****A****O** - **P**indolol, **A**cebutolol, **A**lprenolol, **O**xprenolol). * **Clinical Use:** Drugs with ISA are preferred in hypertensive patients who have pre-existing bradycardia or a low cardiac reserve. * **Contraindication:** Beta-blockers with ISA are generally avoided in patients with angina or post-myocardial infarction because they do not reduce the resting heart rate or myocardial oxygen demand as effectively as pure antagonists.

Q: A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Amiodarone. **Explanation:** The patient is presenting with symptoms of **hypothyroidism** (fatigue, weight gain) despite being on stable L-thyroxine therapy. The temporal relationship between starting an anti-arrhythmic and the onset of symptoms points toward **Amiodarone**. **Why Amiodarone is the correct answer:** Amiodarone is a Class III anti-arrhythmic drug that is structurally unique because it contains approximately **37% iodine by weight**. It affects thyroid function through two primary mechanisms: 1. **Inhibition of 5’-deiodinase:** It blocks the peripheral conversion of T4 to the active T3. 2. **Wolff-Chaikoff Effect:** The high iodine content can lead to a transient or sustained inhibition of thyroid hormone synthesis. In patients with pre-existing thyroid disease (like this patient with a 10-year history), the thyroid may fail to "escape" this effect, leading to **Amiodarone-Induced Hypothyroidism (AIH)**. **Why other options are incorrect:** * **Lignocaine (Class Ib):** Primarily a sodium channel blocker used for ventricular arrhythmias; it has no effect on iodine metabolism or thyroid function. * **Procainamide (Class Ia):** Known for causing Drug-Induced Lupus Erythematosus (DILE), but it does not interfere with the thyroid axis. * **Verapamil (Class IV):** A calcium channel blocker used for supraventricular tachycardia; it does not impact thyroid hormone levels. **NEET-PG High-Yield Pearls:** * **Amiodarone-Induced Thyrotoxicosis (AIT):** Amiodarone can also cause hyperthyroidism via Type 1 (excess iodine substrate) or Type 2 (destructive thyroiditis). * **Half-life:** Amiodarone has an exceptionally long half-life (~weeks to months) due to its high lipid solubility. * **Monitoring:** Patients on Amiodarone require baseline and periodic **Thyroid Function Tests (TFTs)** and **Liver Function Tests (LFTs)**, along with monitoring for pulmonary fibrosis and corneal microdeposits.

Q: Pulsus Bigeminus is a potential side effect of which class of medications?

Cardiac glycosides. **Explanation:** **Pulsus Bigeminus** is a clinical finding where heartbeats occur in pairs—a normal sinus beat followed closely by a premature ventricular contraction (PVC), followed by a compensatory pause. **Why Cardiac Glycosides (e.g., Digoxin) are correct:** Digoxin toxicity is the most common cause of Pulsus Bigeminus. Digoxin inhibits the **Na+/K+ ATPase pump**, leading to an increase in intracellular sodium and, subsequently, intracellular calcium via the Na+/Ca2+ exchanger. While this increases contractility (positive inotropy), excessive calcium levels cause **delayed after-depolarizations (DADs)**. These DADs trigger premature ventricular beats, resulting in the characteristic bigeminal rhythm. **Why other options are incorrect:** * **Beta-adrenergic blockers:** These typically cause bradycardia or heart blocks (AV block) by slowing conduction through the AV node, but they do not typically trigger ectopic ventricular beats. * **ACE Inhibitors:** These primarily affect the renin-angiotensin system to lower blood pressure and do not have direct arrhythmogenic effects on the cardiac conduction system. * **Calcium Channel Blockers (CCBs):** Verapamil and Diltiazem slow the heart rate and can cause AV block, but they are actually used to *treat* certain arrhythmias rather than causing bigeminy. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest sign of Digoxin toxicity:** Anorexia, nausea, and vomiting. * **Most common arrhythmia in Digoxin toxicity:** Ventricular Bigeminy. * **Most characteristic/specific arrhythmia:** Paroxysmal Atrial Tachycardia (PAT) with AV block. * **Electrolyte triggers:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. * **Visual disturbance:** Xanthopsia (yellow-green halos around lights) is a classic board-style symptom of toxicity.

Q: Which of the following is NOT an adverse effect of Losartan?

Cough. **Explanation:** **Losartan** is an Angiotensin II Receptor Blocker (ARB) that selectively antagonizes the $AT_1$ receptor. **Why "Cough" is the correct answer:** Dry cough is a classic side effect of **ACE Inhibitors** (e.g., Enalapril), not ARBs. ACE inhibitors prevent the breakdown of **bradykinin** and **Substance P** in the lungs; the accumulation of these pro-inflammatory autacoids irritates the bronchial mucosa, leading to a persistent dry cough. Since Losartan acts downstream of ACE and does not interfere with bradykinin metabolism, it is characteristically "cough-neutral" and is the preferred alternative for patients who develop a cough on ACE inhibitors. **Analysis of incorrect options:** * **Angioedema:** While much rarer than with ACE inhibitors, angioedema can still occur with ARBs (likely due to $AT_2$ receptor overstimulation or indirect effects on the kinin system). * **Hyperkalemia:** Both ACE inhibitors and ARBs decrease Aldosterone secretion. Reduced aldosterone leads to potassium retention, making hyperkalemia a significant risk, especially in patients with renal impairment or those on K-sparing diuretics. * **Headache:** This is one of the most commonly reported non-specific side effects of Losartan, along with dizziness and fatigue. **High-Yield NEET-PG Pearls:** 1. **Teratogenicity:** Like ACE inhibitors, Losartan is **contraindicated in pregnancy** (causes fetal renal dysgenesis and skull hypoplasia). 2. **Uricosuric Effect:** Losartan is unique among ARBs as it inhibits the URAT1 transporter, increasing uric acid excretion. It is the drug of choice for hypertensive patients with **Gout**. 3. **First-pass metabolism:** Losartan undergoes significant metabolism to its active metabolite, **EXP3174**, which is a more potent non-competitive antagonist than the parent drug.

Q: What is the only FDA-approved therapeutic use of Endothelium-Derived Relaxing Factor?

Pulmonary hypertension in newborns. **Explanation:** **Endothelium-Derived Relaxing Factor (EDRF)** is chemically identified as **Nitric Oxide (NO)**. It is a potent endogenous vasodilator that acts by stimulating soluble guanylyl cyclase, increasing intracellular cGMP, and leading to smooth muscle relaxation. **Why Option A is Correct:** The only FDA-approved clinical use for inhaled Nitric Oxide is **Persistent Pulmonary Hypertension of the Newborn (PPHN)**. In newborns with hypoxic respiratory failure, inhaled NO acts as a **selective pulmonary vasodilator**. Because it is rapidly inactivated by binding to hemoglobin upon entering the systemic circulation, it reduces pulmonary vascular resistance without causing systemic hypotension. **Why Other Options are Incorrect:** * **Option B (Primary Pulmonary Hypertension):** While NO can be used during "vasoreactivity testing" to identify responders in adults, it is not the primary FDA-approved therapeutic treatment. Drugs like Bosentan (Endothelin antagonist) or Sildenafil (PDE-5 inhibitor) are preferred for long-term management. * **Option C (Congestive Cardiac Failure):** NO is not used here as it does not address myocardial contractility and could potentially worsen left-sided heart failure by increasing pulmonary venous return. * **Option D (Essential Hypertension):** NO is administered via inhalation and has a very short half-life (seconds). It is impractical and ineffective for treating systemic (essential) hypertension. **High-Yield NEET-PG Pearls:** * **Mechanism:** NO → ↑ cGMP → Protein Kinase G → Vasodilation. * **Diagnostic Use:** Inhaled NO is used in the cardiac cath lab to differentiate reversible from irreversible pulmonary hypertension. * **Toxicity:** Monitor for **Methemoglobinemia** and Nitrogen Dioxide (NO₂) toxicity during administration. * **Synergy:** Sildenafil potentiates the effects of NO by inhibiting the breakdown of cGMP.

Question 1

Monday disease is associated with exposure to which of the following substances?

Accepted Answer

Nitroglycerine

Answer

Verapamil

Answer

Benzodiazepines

Answer

Propranolol

Question 2

Which beta-blocker possesses antioxidant properties?

Accepted Answer

Carvedilol

Answer

Celiprolol

Answer

Betaxolol

Answer

Propranolol

Question 3

Levosimendan is approved in which of the following conditions?

Accepted Answer

Heart failure

Answer

Kidney failure

Answer

Liver failure

Answer

Endocrine crisis

Question 4

Which of the following is used to treat severe pulmonary hypertension?

Accepted Answer

Bosentan

Answer

Angiotensin I

Answer

Omapatrilat

Answer

Endothelin

Question 5

A hypertensive patient on beta-blocker medication develops severe bradycardia. Which of the following is least likely to be the responsible agent?

Accepted Answer

Pindolol

Answer

Metoprolol

Answer

Nadolol

Answer

Atenolol

Question 6

A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Accepted Answer

Amiodarone

Answer

Lignocaine

Answer

Procainamide

Answer

Verapamil

Question 7

Pulsus Bigeminus is a potential side effect of which class of medications?

Accepted Answer

Cardiac glycosides

Answer

Beta-adrenergic blockers

Answer

Angiotensin-converting enzyme inhibitors

Answer

Calcium channel blockers

Question 8

Which of the following is NOT an adverse effect of Losartan?

Accepted Answer

Cough

Answer

Angioedema

Answer

Hyperkalemia

Answer

Headache

Question 9

Which of the following is not a common side effect for ACE inhibitors and Angiotensin receptor blockers?

Accepted Answer

Dry cough

Answer

Postural hypotension

Answer

Hyperkalemia

Answer

None of the above

Question 10

What is the only FDA-approved therapeutic use of Endothelium-Derived Relaxing Factor?

Accepted Answer

Pulmonary hypertension in newborns

Answer

Primary pulmonary hypertension

Answer

Congestive cardiac failure

Answer

Essential hypertension in newborns

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?